Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULFAMETHOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULFAMETHOPRIM.
MICROSUL vs SULFAMETHOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Sulfamethoprim is a combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, also blocking folic acid synthesis. This sequential blockade produces bactericidal effects.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
Oral or intravenous: 800 mg sulfamethoxazole / 160 mg trimethoprim every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Terminal elimination half-life: 8-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary: 5-10%; fecal: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic